These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33245444)

  • 21. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing your patient with gout: a review of treatment options.
    Doghramji PP
    Postgrad Med; 2011 May; 123(3):56-71. PubMed ID: 21566416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations in clinical practice guidelines on gout: systematic review and consistency analysis.
    Yu Y; Wang D; Zhou Q; Wang C; Ma X; Gao Y; Song X; Xiao S; Wang Q; Zeng X; Estill J; Qian Z; Chen Y
    Clin Exp Rheumatol; 2020; 38(5):964-972. PubMed ID: 31969230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
    Goossens J; Lancrenon S; Lanz S; Ea HK; Lambert C; Guggenbuhl P; Saraux A; Delva C; Sahbane S; Lioté F
    Joint Bone Spine; 2017 Jul; 84(4):447-453. PubMed ID: 28411137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
    Roddy E; Packham J; Obrenovic K; Rivett A; Ledingham JM
    Rheumatology (Oxford); 2018 May; 57(5):826-830. PubMed ID: 29447370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial.
    Satpanich P; Pongsittisak W; Manavathongchai S
    Clin Rheumatol; 2022 Jan; 41(1):213-221. PubMed ID: 34406530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gout].
    Tausche AK
    Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Challenges of Approaching and Managing Gout.
    Fields TR
    Rheum Dis Clin North Am; 2019 Feb; 45(1):145-157. PubMed ID: 30447743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout: treat to avoiding symptoms versus treat to target.
    Jansen TL; Janssen M
    Clin Rheumatol; 2017 Nov; 36(11):2399-2402. PubMed ID: 28920180
    [No Abstract]   [Full Text] [Related]  

  • 37. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of complex gout in clinical practice: Update on therapeutic approaches.
    Narang RK; Dalbeth N
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):813-834. PubMed ID: 31427057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenges of managing gout in primary care: Results of a best-practice audit.
    Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
    Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
    Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.